CoChat

Ezetimibe improves postprandial hyperlipidaemia in patients with type IIb hyperlipidaemia

Open access
Masuda, D., Nakagawa‐Toyama, Y., Nakatani, K., Inagaki, M., Tsubakio‐Yamamoto, K., Sandoval, J. C., Ohama, T., Nishida, M., Ishigami, M., Yamashita, S. · 2009 · European Journal of Clinical Investigation
Cited by 83

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Abstract

Background Postprandial hyperlipidaemia is known to be a high‐risk factor for atherosclerotic disease because of rapid and lasting accumulations of triglyceride‐rich lipoproteins and remnants. The Niemann‐Pick C1‐Like 1 (NPC1L1) protein acts as an intestinal cholesterol transporter and ezetimibe, which inhibits NPC1L1, has been used in patients with hypercholesterolaemia. We investigated effects of ezetimibe on fasting lipid and lipoprotein profiles and postprandial hyperlipidaemia in patients with type IIb hyperlipidaemia. Materials and methods Ezetimibe 10 mg per day was administered in ten patients with type IIb hyperlipidaemia for 2 months, and lipid and lipoprotein profiles were examined during fasting and after an oral fat loading (OFL) test. Results In the fasting state, ezetimibe significantly decreased not only total cholesterol, low density lipoprotein (LDL)‐cholesterol and apolipoproteinB‐100 (apoB‐100) levels but triglycerides (TG), apoB‐48 and remnant lipoprotein cholesterol (RemL‐C) levels. High performance liquid chromatography analysis showed that ezetimibe decreased cholesterol and TG levels in the very low density lipoprotein (VLDL) and LDL size ranges as well as apoB‐100 levels, suggesting a decrease in numbers of VLDL and LDL particles. After OFL, ezetimibe decreased the area under the curve for TG, apoB‐48 and RemL‐C. Ezetimibe decreased postprandial elevations of cholesterol and TG levels in the chylomicrons (CM) size range, suggesting that the postprandial production of CM particles was suppressed by ezetimibe. Conclusions These findings suggest that ezetimibe improves fasting lipoprotein profiles and postprandial hyperlipidaemia by suppressing intestinal CM production in patients with type IIb hyperlipidaemia and such treatment may prove to be effective in reducing atherosclerosis.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1365-2362.2009.02163.x

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 83

Metadata

Authors
Masuda, D., Nakagawa‐Toyama, Y., Nakatani, K., Inagaki, M., Tsubakio‐Yamamoto, K., Sandoval, J. C., Ohama, T., Nishida, M., Ishigami, M., & Yamashita, S.
Venue
European Journal of Clinical Investigation
Publisher
Wiley
Published
2009-07-03
Volume
39
Issue
8
Pages
689-698
ISSN
  • 0014-2972 (ISSN-L)
  • 1365-2362
OpenAlex
W2136368727
Cited by
83
References
1
FWCI
12.30
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Ezetimibe improves postprandial hyperlipidaemia in patients with type IIb hyperlipidaemia. https://app.cochat.ai/papers/10.1111/j.1365-2362.2009.02163.x
The paper
Masuda, D., Nakagawa‐Toyama, Y., Nakatani, K., Inagaki, M., Tsubakio‐Yamamoto, K., Sandoval, J. C., Ohama, T., Nishida, M., Ishigami, M., & Yamashita, S. (2009). Ezetimibe improves postprandial hyperlipidaemia in patients with type IIb hyperlipidaemia. European Journal of Clinical Investigation. https://doi.org/10.1111/j.1365-2362.2009.02163.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.